EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
12.85
-0.45 (-3.38%)
Jul 20, 2026, 2:36 PM EDT - Market open
EyePoint Revenue
EyePoint had revenue of $696.00K in the quarter ending March 31, 2026, a decrease of -97.15%. This brings the company's revenue in the last twelve months to $7.62M, down -86.41% year-over-year. In the year 2025, EyePoint had annual revenue of $31.37M, down -27.50%.
Revenue (ttm)
$7.62M
Revenue Growth
-86.41%
P/S Ratio
146.45
Revenue / Employee
$35,579
Employees
214
Market Cap
1.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.37M | -11.90M | -27.50% |
| Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
| Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
| Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
| Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
| Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
| Dec 31, 2019 | 20.37M | 15.79M | 345.53% |
| Dec 31, 2018 | 4.57M | 1.61M | 54.37% |
| Jun 30, 2018 | 2.96M | -4.58M | -60.72% |
| Jun 30, 2017 | 7.54M | 5.92M | 365.37% |
| Jun 30, 2016 | 1.62M | -24.95M | -93.90% |
| Jun 30, 2015 | 26.57M | 23.09M | 664.90% |
| Jun 30, 2014 | 3.47M | 1.33M | 62.06% |
| Jun 30, 2013 | 2.14M | -1.38M | -39.22% |
| Jun 30, 2012 | 3.53M | -1.44M | -28.98% |
| Jun 30, 2011 | 4.97M | -18.09M | -78.46% |
| Jun 30, 2010 | 23.05M | 10.89M | 89.55% |
| Jun 30, 2009 | 12.16M | 8.69M | 249.88% |
| Jun 30, 2008 | 3.48M | 1.69M | 94.73% |
| Jun 30, 2007 | 1.79M | 749.00K | 72.30% |
| Jun 30, 2006 | 1.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 79.76M |
| Wave Life Sciences | 71.80M |
| Lexicon Pharmaceuticals | 69.64M |
| Capricor Therapeutics | 11.13M |
| Inventiva | 7.94M |
| Avalo Therapeutics | 59.00K |
EYPT News
- 3 days ago - EyePoint to pay $4.6M to resolve False Claim Act allegations - TheFly
- 4 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - EyePoint initiated with a Buy at Stifel - TheFly
- 7 days ago - EyePoint appoints Tarek Hassan as chief strategic science officer - TheFly
- 7 days ago - EyePoint Appoints Tarek S. Hassan, M.D. - GlobeNewsWire
- 12 days ago - EyePoint assumed with an Overweight at Cantor Fitzgerald - TheFly
- 18 days ago - Robinhood and 4 More Stocks That Were Just Added to This Firm's ‘Top Picks' List - Barrons
- 19 days ago - EyePoint price target raised to $65 from $29 at Chardan - TheFly